SEC Comment Letter 0000000000-26-005723 to Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc.
Date: June 5, 2026 · CIK: 0001422142 · Accession: 0000000000-26-005723
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296353
Letter
June 5, 2026 David Lennon Chief Executive Officer Whitehawk Therapeutics, Inc. 2 Headquarters Plaza East Building, 11th Floor Morristown, NJ 07960 Re: Whitehawk Therapeutics, Inc. Registration Statement on Form S-3 Filed May 29, 2026 File No. 333-296353 Dear David Lennon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rob Wernli
Show Raw Text
June 5, 2026 David Lennon Chief Executive Officer Whitehawk Therapeutics, Inc. 2 Headquarters Plaza East Building, 11th Floor Morristown, NJ 07960 Re: Whitehawk Therapeutics, Inc. Registration Statement on Form S-3 Filed May 29, 2026 File No. 333-296353 Dear David Lennon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rob Wernli